Skip to main content

Pharmacielo Ltd(PCLO-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.050
Day High0.055
Open:0.050
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: PharmaCielo Ltd.
Newsfile
PharmaCielo Announces Intention to Issue Interest Shares
INK Research
Multiple insider buying at PharmaCielo (PCLO)
Company Chart of PCLO
Newsfile
PharmaCielo Announces the Issuance of Interest Shares
Newsfile
PharmaCielo Announces 2025 Q3 Results, AGM Details
Newsfile
Upcoming Meeting Dates - February 9, 2026
Newsfile
PharmaCielo Announces Revocation of FFCTO and Related Corporate Matters
GlobeNewswire
PharmaCielo Completes La Margarita Land Sale, Repays Banco Agrario Loan, Strengthens Balance Sheet, Completes Audit
PR Newswire
Canadian Investment Regulatory Organization Trading Halt - PCLO
AI-generated - The Globe and Mail
PharmaCielo: Top 25 Undervalued TSX Venture Exchange Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Drug Manufacturers Industry Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 25 Undervalued TSX Venture Exchange Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Drug Manufacturers Industry Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 25 Undervalued TSX Venture Exchange Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Drug Manufacturers Industry Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Drug Manufacturers Industry Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Drug Manufacturers Industry Stocks (PCLO)
Newsfile
PharmaCielo Reports Q4 2024 Financial Results
AI-generated - The Globe and Mail
PharmaCielo: Top 25 Undervalued TSX Venture Exchange Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Drug Manufacturers Industry Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (PCLO)
Newsfile
PharmaCielo Announces Issuance of Shares for Settlement of Certain Amounts Owing
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Drug Manufacturers Industry Stocks (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Drug Manufacturers Industry Stocks (PCLO)
Newsfile
PharmaCielo Reports Q3 2024 Financial Results
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (PCLO)
AI-generated - The Globe and Mail
PharmaCielo: Top 10 Undervalued Drug Manufacturers Industry Stocks (PCLO)
Newsfile
PharmaCielo Announces Intention to Extend Expiry Date of Warrants
Newsfile
PharmaCielo Announces Change to Financial Year-End, and Appointment of Davidson & Company LLP as Auditor Effective October 7, 2024
Newsfile
PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2024
Newsfile
CORRECTION FROM SOURCE: PharmaCielo Provides Update on Reinstatement for Trading

Profile

PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.